Skip to content

Understanding how a compound is absorbed, metabolised and excreted in vivo is vital to any drug development program. IRBM prides itself on its rapid and cost-effective assays that provide effective surrogates and indicators for the fate of compounds in vivo.

We apply a comprehensive and holistic approach to predicting the fate of drugs in humans that can also provide early data on human dose prediction. Our suite of in silico (LogD, LogP, pka, TPSA), in vitro, (permeability, and metabolic stability), and in vivo (screening IV PK) assays ensure we home in rapidly on molecules that display optimal potency, clearance, MRT, and bioavailability.

With a focus on quality and efficiency, we work closely with our partners to customise the ADME screening cascade and to  optimise the assay schedule according to compound properties and  number and assay throughput rate.

FIND OUT MORE ABOUT OUR DEDICATED RESEARCH TEAMS:

DISTRIBUTION

  • Plasma protein binding across species
    (rapid equilibrium dialysis (RED), and TRANSIL PPB Binding Kit)
  • Microsomal binding
  • Cell media and tissue protein binding
  • Blood cell partitioning

METABOLISM

  • Metabolic stability: hepatic and extrahepatic (microsomes, S9, hepatocytes): Phase 1 and 2; CYP-mediated and non-CYP mediated
  • Tissue stability (Subcutaneous tissue and other organs)
  • CYP inhibition and induction in qualified hepatocytes
  • Time dependent inhibition/mechanism dependent inhibition/drug-drug interactions

IN VITRO TOXICOLOGY

  • Mast Cell Degranulation (hLAD2)
  • hERG inhibition assay
  • OATP1B1 inhibition assay

PERMEABILITY/TRANSPORTERS

  • PAMPA
  • MDCKII, MDCKII-MDR1, and MDCKII-BCRP permeability
  • iPSC derived hBBB permeability
FIND OUT MORE ABOUT OUR CROSS FUNCTIONAL DRUG DISCOVERY SERVICES

PK, PD
BIOANALYTICS

BIOTRANSFORMATION,
BIODISTRIBUTION,
ANALYTICAL
SCIENCE

Back To Top